Regeneron Pharmaceuticals (REGN) Set to Release Quarterly Earnings on Friday

Key Points

• Regeneron is expected to report Q3 2026 results before market open on October 30. Analysts anticipate earnings of $16.20 per share on $4.56 billion in revenue.
• The company’s previous quarter exceeded expectations, with EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion versus $3.82 billion expected. Revenue increased 16.7% year over year.
• Regeneron shares recently traded at $819.09, while analysts maintain a “Moderate Buy” consensus and an average price target of $846.28; the company also pays a quarterly dividend of $0.94 per share.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect the company to announce earnings of $16.20 per share and revenue of $4.56 billion for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, October 30, 2026 at 8:30 AM ET.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm's revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $12.81 EPS. On average, analysts expect Regeneron Pharmaceuticals to post $48.87 EPS for the current fiscal year and $52.95 EPS for the next fiscal year.

Regeneron Pharmaceuticals Stock Up 1.7%

Regeneron Pharmaceuticals stock opened at $819.09 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The business's 50-day simple moving average is $791.83 and its two-hundred day simple moving average is $722.58. The company has a market cap of $84.33 billion, a PE ratio of 20.68, a PEG ratio of 1.37 and a beta of 0.16. Regeneron Pharmaceuticals has a fifty-two week low of $572.75 and a fifty-two week high of $859.34.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 9.29%.

Insiders Place Their Bets

In related news, insider Andrew Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares in the company, valued at $36,960,559.10. The trade was a 7.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the company's stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the transaction, the executive vice president directly owned 12,003 shares of the company's stock, valued at $10,291,252.17. The trade was a 8.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,093 shares of company stock valued at $6,506,845 over the last quarter. Insiders own 6.97% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on REGN. Benchmark raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price target for the company in a research report on Tuesday, July 7th. HSBC lifted their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a "buy" rating in a research report on Thursday, September 10th. Raymond James Financial raised their price objective on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. JPMorgan Chase & Co. lifted their target price on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an "overweight" rating in a report on Tuesday, October 6th. Finally, Robert W. Baird lifted their target price on shares of Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a "neutral" rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $846.28.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.